Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have covered the stock in the last year is $35.00.
ANRO has been the subject of several research analyst reports. Rodman & Renshaw began coverage on shares of Alto Neuroscience in a research note on Friday, June 21st. They set a “buy” rating and a $43.00 price target for the company. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Wednesday, June 12th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $32.00 price target on shares of Alto Neuroscience in a research report on Monday, March 25th.
View Our Latest Stock Report on ANRO
Alto Neuroscience Trading Down 0.2 %
Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.30). On average, research analysts anticipate that Alto Neuroscience will post -2.93 earnings per share for the current year.
Insider Transactions at Alto Neuroscience
In related news, insider Adam Savitz acquired 12,069 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The shares were acquired at an average price of $12.60 per share, with a total value of $152,069.40. Following the acquisition, the insider now owns 36,920 shares of the company’s stock, valued at approximately $465,192. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Institutional Trading of Alto Neuroscience
Several institutional investors and hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. bought a new position in shares of Alto Neuroscience in the first quarter worth $21,267,000. Price T Rowe Associates Inc. MD bought a new position in Alto Neuroscience in the 1st quarter worth about $9,788,000. Vanguard Group Inc. purchased a new stake in shares of Alto Neuroscience in the 1st quarter valued at about $8,233,000. Jennison Associates LLC bought a new stake in shares of Alto Neuroscience during the 1st quarter valued at about $7,039,000. Finally, Artal Group S.A. purchased a new position in shares of Alto Neuroscience during the first quarter worth about $5,372,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Recommended Stories
- Five stocks we like better than Alto Neuroscience
- Dividend Payout Ratio Calculator
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- How to Choose Top Rated Stocks
- Has This Leading Tech Stock Halted the AI Surge?
- Bank Stocks – Best Bank Stocks to Invest In
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.